Clinical feasibility of fast 3-dimensional dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90Y-microspheres

Journal of Nuclear Medicine

Volumn 52, Issue 12, 2011, Pages 1930-1937

  Dieudonné, Arnaud ^a,b   Garin, Etienne ^c   Laffont, Sophie ^c   Rolland, Yan ^c   Lebtahi, Rachida ^a,b,d   Leguludec, Dominique ^a,d   Gardin, Isabelle ^e,f  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c Department of Nuclear Medicine   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITÉ DE ROUEN   (France)

^f CENTRE HENRI BECQUEREL   (France)

Author keywords

3D dosimetry; 90Y; Microspheres; SIRT; TARE; Voxel S values

Indexed keywords

MACROSALB TC 99M; MICROSPHERE; MICROSPHERE Y 90; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSIMETRY; DRUG ABSORPTION; DRUG TARGETING; FEASIBILITY STUDY; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RADIATION DOSE; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL DOSIMETRY; TREATMENT PLANNING; TUMOR VOLUME; VOXEL BASED MORPHOMETRY;

CARCINOMA, HEPATOCELLULAR; FEASIBILITY STUDIES; HUMANS; LIVER; LIVER NEOPLASMS; MICROSPHERES; ORGANS AT RISK; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; SOFTWARE; TIME FACTORS; YTTRIUM RADIOISOTOPES;

EID: 83755161877     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.095232     Document Type: Article

References (31)

1. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1 - technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-1278. (Pubitemid 44259009)
2. Gulec SA, Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres. J Nucl Med. 2007;48:2080-2086. (Pubitemid 350232320)
3. Ahmadzadehfar H, Biersack H, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40:105-121.
4. Abdalla EK, Vauthey J, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825, discussion 825-827.
5. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Haken Ten RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810-821. (Pubitemid 34722625)
6. Naymagon S, Warner RRP, Patel K, et al. Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature. Dig Dis Sci. 2010;55:2450-2458.
7. Aloia TA, Barakat O, Connelly J, et al. Gastric radiation enteritis after intraarterial yttrium-90 microsphere therapy for early stage hepatocellular carcinoma. Exp Clin Transplant. 2009;7:141-144.
8. Murthy R, Brown DB, Salem R, et al. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol. 2007;18:553-561. (Pubitemid 46566540)
9. Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31:431-438.
10. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919-924.
11. Sirtex Medical. Sirtex Medical Training Manual: Training Program Physicians and Institutions. Lane Cove, New South Wales, Australia: Sirtex Medical.
12. Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947-952. (Pubitemid 26278795)
13. 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47:1209-1211.
14. TheraSphere® Yttrium-90 Glass Microspheres [package insert]. 2005. Available at: http://www.mdsnordion.com/. Accessed November 3, 2011.
15. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. Revised. New York, NY: The Society of Nuclear Medicine; 1991.
16. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23. (Pubitemid 46589861)
17. 90Y microspheres in patients with hepatocellular cancer. J Nucl Med. 2009;50:688-692.
18. 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51:1206-1212.
19. Dieudonné A, Hobbs RF, Bolch WE, Sgouros G, Gardin I. Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel size. J Nucl Med. 2010;51:1600-1607.
20. Gardin I, Bouchet LG, Assié K, et al. Voxeldose: a computer program for 3-D dose calculation in therapeutic nuclear medicine. Cancer Biother Radiopharm. 2003;18:109-115. (Pubitemid 36307472)
21. Bolch WE, Bouchet LG, Robertson JS, et al. MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions - radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med. 1999;40(suppl):11S-36S. (Pubitemid 29044199)
22. Hendricks JS, McKinney GW, Waters SW. MCNPX Extended Version 2.5.0. LA-UR-05-2675. Los Alamos, NM: Los Alamos National Laboratory; 2005.
23. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JH. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13:S223-S229.
24. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583-592. (Pubitemid 28104228)
25. Sarfaraz M, Kennedy AS, Lodge MA, Li XA, Wu X, Yu CX. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys. 2004;31:2449-2453. (Pubitemid 39287858)
26. Buffa FM, Verhaegen F. Backscatter and dose perturbations for low- to medium-energy electron point sources at the interface between materials with different atomic numbers. Radiat Res. 2004;162:693-701. (Pubitemid 39552899)
27. 90Y microsphere treatment: A Monte Carlo modeling approach based on lobular microanatomy. J Nucl Med. 2010;51:301-310.
28. 90Y permits hepatic localization of microspheres using routine PET: proof of concept. J Nucl Med. 2011;52:72-76.
29. 90Y therapy of liver cancer. Technol Cancer Res Treat. 2010;9:253-262.
30. Lee IJ, Seong J, Shim SJ, Han KH. Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:154-158.
31. Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J. 2009;50:601-612.